Top Story

Francesco Rubino, MD: 'Converting' bariatric surgery into a diabetes intervention poses challenges

October 24, 2014

BOSTON — Converting a procedure that has been used for years as a weight-loss intervention into a treatment aimed primarily at diabetes or metabolic disease poses an important challenge with several ramifications, according to Francesco Rubino, MD, professor and chair of bariatric and metabolic surgery at King's College London in London.

While evidence has emerged that gastrointestinal surgery can improve diabetes, reduce cardiometabolic risk and prolong survival, indications for bariatric surgery are primarily based on weight, which poses a barrier to access for many patients, he said.

figure Meeting News Coverage

Cardiometabolic Health Congress highlights latest research on CVD, diabetes, obesity

October 23, 2014
BOSTON — The latest innovative research in diabetes, hypertension, lipids, obesity and thrombosis was analyzed by experts at the Cardiometabolic Health…
In the Journals

Atherosclerosis risk increased among men with diabetes, low testosterone

October 17, 2014
A greater risk for developing atherosclerosis is found among middle-aged men with low testosterone and type 2 diabetes, according to recent study findings published in…
Meeting News Coverage

Biguanides, liraglutide reduced CVD risk in type 2 diabetes

September 24, 2014
Patients with type 2 diabetes treated with biguanides and liraglutide have a reduced risk for ischemic heart disease, heart failure and stroke, according to research…
CME
figure

Practical Lipidology: 2013

This activity is supported by an educational grant from Genentech.

The rise in the prevalence of obesity in the last few decades and its growing impact on health has driven the…
More »
Meeting News Coverage Video
figure

Francesco Rubino, MD: 'Converting' bariatric surgery into a diabetes intervention poses challenges

October 24, 2014
BOSTON — Converting a procedure that has been used for years as a weight-loss intervention into a treatment aimed…
More »
CME
figure

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »

Filter By:

In the Journals

Hyperglycemia at hospitalization increased risk for future diabetes in MI patients

March 14, 2014
Approximately one in six patients hospitalized for acute MI have hyperglycemia without known diabetes, and these patients are at a 2.5-fold increased…
In the Journals

Cardiac death, MI remain increased in patients with diabetes treated with DES

March 13, 2014
Among patients treated with drug-eluting stents during the DES era, researchers observed a higher rate of death or MI in those with diabetes compared…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

March 12, 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

Cardiology Today, April 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

March 7, 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

Cardiology Today, April 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
FDA approvals Perspective

FDA approves Myalept for treatment of lipodystrophy

February 25, 2014
The FDA today approved metreleptin, in combination with diet, for the treatment of complications of leptin deficiency in patients with congenital…

FDA to review heart failure risk associated with saxagliptin

February 11, 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…
FDA News

FDA to review heart failure risk associated with saxagliptin

Cardiology Today, April 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…

CVS plans to stop all tobacco sales

February 6, 2014
CVS Caremark has announced that it will eliminate the sale of cigarettes and other tobacco products in all of its US pharmacies by October.There are…
More Headlines »